Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.05 | N/A | -150.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.05 | N/A | -150.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, indicating awareness of challenges ahead. They refrained from providing any forward guidance.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges but did not elaborate on specific strategies.
Ligand Pharmaceuticals reported a loss per share of $-0.05, which was below expectations. The stock reacted negatively, dropping 0.59%. The lack of revenue data and forward guidance adds uncertainty for investors, contributing to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STIFEL FINL CORP
Nov 5, 2007